Dissemin is shutting down on January 1st, 2025

Published in

Nature Research, Nature Communications, 1(13), 2022

DOI: 10.1038/s41467-022-33407-5

arXiv, 2022

DOI: 10.48550/arxiv.2204.10836

Links

Tools

Export citation

Search in Google Scholar

Federated Learning Enables Big Data for Rare Cancer Boundary Detection

Journal article published in 2022 by Sarthak Pati ORCID, Sebastian R. van der Voort ORCID, Ujjwal Baid ORCID, Brandon Edwards ORCID, G. Anthony Reina, Micah Sheller, Shih-Han Wang, G. Anthony Reina, Patrick Foley ORCID, Alexey Gruzdev, Deepthi Karkada ORCID, Christos Davatzikos ORCID, Chiharu Sako ORCID, Satyam Ghodasara ORCID, Michel Bilello and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Although machine learning (ML) has shown promise in numerous domains, there are concerns about generalizability to out-of-sample data. This is currently addressed by centrally sharing ample, and importantly diverse, data from multiple sites. However, such centralization is challenging to scale (or even not feasible) due to various limitations. Federated ML (FL) provides an alternative to train accurate and generalizable ML models, by only sharing numerical model updates. Here we present findings from the largest FL study to-date, involving data from 71 healthcare institutions across 6 continents, to generate an automatic tumor boundary detector for the rare disease of glioblastoma, utilizing the largest dataset of such patients ever used in the literature (25,256 MRI scans from 6,314 patients). We demonstrate a 33% improvement over a publicly trained model to delineate the surgically targetable tumor, and 23% improvement over the tumor's entire extent. We anticipate our study to: 1) enable more studies in healthcare informed by large and diverse data, ensuring meaningful results for rare diseases and underrepresented populations, 2) facilitate further quantitative analyses for glioblastoma via performance optimization of our consensus model for eventual public release, and 3) demonstrate the effectiveness of FL at such scale and task complexity as a paradigm shift for multi-site collaborations, alleviating the need for data sharing.